drugset / Trial / NCT04151563
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
Phase 1/2
Withdrawn
Bristol-Myers Squibb
Clovis Oncology, Inc. · collabEli Lilly and Company · collabExelixis · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
Timeline
- Start
- 2021-04-15
- Primary completion
- 2023-12-17
- Completion
- 2026-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Lucitanib | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Ramucirumab | Monoclonal antibody | — | — |